HC Wainwright Has Bearish Estimate for Alumis Q3 Earnings

Alumis Inc. (NASDAQ:ALMS) – HC Wainwright reduced their Q3 2026 earnings estimates for Alumis in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.70) per share for the quarter, down from their previous forecast of ($0.69). HC Wainwright has a “Neutral” rating and a $25.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($2.87) per share. HC Wainwright also issued estimates for Alumis’ Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($2.96) EPS, Q1 2027 earnings at ($0.74) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.76) EPS, Q4 2027 earnings at ($0.65) EPS and FY2027 earnings at ($2.91) EPS.

Several other analysts also recently issued reports on the company. Guggenheim raised their price target on Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Morgan Stanley restated an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research note on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. Wall Street Zen downgraded shares of Alumis from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Citigroup restated a “neutral” rating on shares of Alumis in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $40.30.

Alumis Trading Up 0.8%

NASDAQ:ALMS opened at $25.50 on Tuesday. The stock has a 50 day moving average of $26.32 and a 200-day moving average of $25.26. The firm has a market capitalization of $3.25 billion, a PE ratio of -6.61 and a beta of -0.69. Alumis has a 52 week low of $3.76 and a 52 week high of $31.35.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%.The business had revenue of $1.66 million during the quarter, compared to the consensus estimate of $3.65 million.

Insider Buying and Selling

In related news, insider Roy C. Hardiman sold 2,692 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $70,988.04. Following the sale, the insider directly owned 207,746 shares in the company, valued at $5,478,262.02. The trade was a 1.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO John R. Schroer sold 3,282 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $86,546.34. Following the sale, the chief financial officer directly owned 24,718 shares of the company’s stock, valued at approximately $651,813.66. This represents a 11.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 19,953 shares of company stock worth $534,311. 33.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System boosted its stake in shares of Alumis by 2,222.5% during the 1st quarter. California State Teachers Retirement System now owns 80,845 shares of the company’s stock worth $1,781,000 after acquiring an additional 77,364 shares in the last quarter. First Trust Advisors LP acquired a new position in shares of Alumis in the 1st quarter worth $1,456,000. The Manufacturers Life Insurance Company raised its position in shares of Alumis by 775.6% during the first quarter. The Manufacturers Life Insurance Company now owns 154,634 shares of the company’s stock worth $3,407,000 after purchasing an additional 136,973 shares during the period. Swiss National Bank acquired a new stake in shares of Alumis during the first quarter worth $2,815,000. Finally, Elmind Capital LP acquired a new stake in shares of Alumis during the first quarter worth $2,864,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.